<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82917">
  <stage>Registered</stage>
  <submitdate>20/06/2008</submitdate>
  <approvaldate>24/06/2008</approvaldate>
  <actrnumber>ACTRN12608000305325</actrnumber>
  <trial_identification>
    <studytitle>Developing a questionnaire to help doctors customise asthma management to the needs of individual patients</studytitle>
    <scientifictitle>A study of adolescents and adults with asthma who are taking inhaled corticosteroid/long-acting beta-2-agonist inhalers (ICS/LABA), to develop a questionnaire to identify factors predicting poor asthma control</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Inhaled salmeterol/fluticasone. Participants will continue to use this medication at the same frequency and dose (or equivalent dose) as was previously prescribed by their own doctor. The duration of observation will be 8 weeks.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Questionnaire items that are most strongly associated with poor asthma control (Asthma Control Test score &lt;20)</outcome>
      <timepoint>Timepoint for questionnaire: Week 0. Timepoint for assessment of asthma control: weeks 5-8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Forced expiratory volume in 1 second (FEV1) % predicted, measured according to European Respiratory Society/American Thoracic Society guidelines for spirometry.</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age =14 yrs
2. Doctor diagnosis of asthma
3. Current prescription for salmeterol/fluticasone or formoterol/budesonide</inclusivecriteria>
    <inclusiveminage>14</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Recent asthma exacerbation (hospitalisation, Emergency Department visit, or steroid tablets for asthma in the previous month)
2. Other major respiratory disease e.g. COPD, or serious uncontrolled medical condition;
3. Patients who are pregnant or lactating or planning pregnancy in the next 2 months
4. Symbicort as Maintenance and Reliever Therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>23/06/2008</anticipatedstartdate>
    <actualstartdate>29/07/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/11/2009</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Woolcock Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>PO Box M77 Missenden Rd, Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Asthma Foundation NSW</fundingname>
      <fundingaddress>Level 3, 486 Pacific Highway, St Leonards NSW 2065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will develop a simple questionnaire to allow health care professionals to identify features contributing to poor asthma control, in patients who are currently using inhaled corticosteroid/long-acting b2-agonist combination inhaler.</summary>
    <trialwebsite />
    <publication>Foster JM, Smith L, Bosnic-Anticevich SZ, Usherwood T, Sawyer SM, Rand CS, et al. Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. Intern Med J. 2012;42(6):e136-44.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney SouthWest Area Health Service Ethics Review Committee (RPAH zone)</ethicname>
      <ethicaddress>Level 8, Building 14, Royal Prince Alfred Hospital, Missenden Rd, Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>2/06/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Helen Reddel</name>
      <address>Woolcock Institute of Medical Research, PO Box M77, Missenden Rd Camperdown NSW 2050.</address>
      <phone>+61 2 9114 0437</phone>
      <fax>+61 2 9114 0014</fax>
      <email>helen.reddel@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Helen Reddel</name>
      <address>Woolcock Institute of Medical Research, PO Box M77, Missenden Rd Camperdown NSW 2050.</address>
      <phone>+61 2 9114 0437</phone>
      <fax>+61 2 9114 0014</fax>
      <email>helen.reddel@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Helen Reddel</name>
      <address>Woolcock Institute of Medical Research, PO Box M77, Missenden Rd Camperdown NSW 2050.</address>
      <phone>+61 2 9114 0437</phone>
      <fax>+61 2 9114 0014</fax>
      <email>helen.reddel@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Helen</name>
      <address>Woolcock Institute of Medical Research
PO Box M77, Missenden Rd Post Office, NSW 2050</address>
      <phone>+61 2 9114 0437</phone>
      <fax />
      <email>helen.reddel@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>